德国科隆大学Florian Klein研究团队报道了埃博拉病毒疫苗rVSV-ZEBOV的多克隆和集中的抗体反应。2019年10月7日，相关论文在线发表在《自然—医学》杂志上。
通过进行全面的单个B细胞和电子显微镜结构分析，研究人员对参加1期rVSV-ZEBOV疫苗接种试验的一部分人类志愿者的体液免疫应答进行了检查。四种研究过的疫苗显示具有共同序列特征的多克隆、可重现和集中的B细胞反应。靶向埃博拉病毒（EBOV）的抗体可与其他埃博拉病毒种交叉反应，详细的表位图谱揭示了与分离自埃博拉病毒疾病（EVD）幸存者抗体重叠的目标表位。此外，在所有疫苗中，研究人员都检测到了高效的EBOV中和抗体，其活性与目前在临床试验中使用的单克隆抗体相当或更高。这些抗体包括结合了IGHV3-15 / IGLV1-40免疫球蛋白基因片段的抗体，这些基因片段在所有受调查的个体中均已鉴定。
这些发现将有助于评估和指导当前和未来的疫苗接种策略，并为新型EVD治疗提供机会。
据研究人员介绍，重组水疱性口炎病毒–扎伊尔埃博拉病毒（rVSV-ZEBOV）是最先进的埃博拉病毒候选疫苗，目前正用于应对刚果民主共和国的埃博拉病毒疾病爆发。
附：英文原文
Title: Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Author: Stefanie A. Ehrhardt, Matthias Zehner, Verena Krähling, Hadas Cohen-Dvashi, Christoph Kreer, Nadav Elad, Henning Gruell, Meryem S. Ercanoglu, Philipp Schommers, Lutz Gieselmann, Ralf Eggeling, Christine Dahlke, Timo Wolf, Nico Pfeifer, Marylyn M. Addo, Ron Diskin, Stephan Becker & Florian Klein
Issue&Volume: 2019-10-07
Abstract:
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC). Here we examine the humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial by performing comprehensive single B cell and electron microscopy structure analyses. Four studied vaccinees show polyclonal, yet reproducible and convergent B cell responses with shared sequence characteristics. EBOV-targeting antibodies cross-react with other Ebolavirus species, and detailed epitope mapping revealed overlapping target epitopes with antibodies isolated from EVD survivors. Moreover, in all vaccinees, we detected highly potent EBOV-neutralizing antibodies with activities comparable or superior to the monoclonal antibodies currently used in clinical trials. These include antibodies combining the IGHV3–15/IGLV1–40 immunoglobulin gene segments that were identified in all investigated individuals. Our findings will help to evaluate and direct current and future vaccination strategies and offer opportunities for novel EVD therapies.
DOI: 10.1038/s41591-019-0602-4
Source:https://www.nature.com/articles/s41591-019-0602-4
Nature Medicine：《自然—医学》，创刊于1995年。隶属于施普林格·自然出版集团，最新IF：87.241
官方网址：https://www.nature.com/nm/
投稿链接：https://mts-nmed.nature.com/cgi-bin/main.plex
本期文章：《自然—医学》：Online/在线发表
